Company profile: Prosetta Biosciences
1.1 - Company Overview
Company description
- Provider of the Prosetta Platform, a drug discovery platform applying small molecules that modulate assembly of multi-protein complexes for infectious and degenerative diseases. Offers antiviral compounds targeting energy-dependent capsid assembly, an oncology program identifying anti-proliferative agents across ~75 cancers, antibacterial and neurodegenerative research, and PAV-431, a host-targeted antiviral effective against multiple respiratory viruses.
Products and services
- Antiviral Compounds: Produces antiviral products that target the energy-dependent capsid assembly process common across diverse viral families, inhibiting capsid formation
- Capsid-targeted
- PAV-431: Builds a small-molecule antiviral chemotype that targets a transient host multi-protein complex and demonstrates effectiveness against multiple respiratory viruses
- Host-directed
- Prosetta Platform: Engineers a drug discovery system for infectious and degenerative diseases, prioritizing small molecules that modulate intra-cellular multi-protein assembly pathways
- Small-molecule–centric
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Prosetta Biosciences
Karius
HQ: United States
Website
- Description: Provider of genomic insights into infectious diseases via the Karius Test, a liquid biopsy detecting over 1,000 pathogens from a single blood sample for rapid, non-invasive diagnosis. Offers microbial cell-free DNA detection, AI-driven real-time analysis against proprietary reference genome databases, and clinical and analytical validation, helping clinicians make critical, life-saving treatment decisions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Karius company profile →
Specific Diagnostics
HQ: United States
Website
- Description: Provider of patented medical device technology leveraging a low-cost small molecule sensor to enable diagnostic products that simplify workflow and speed time-to-answer at a low cost.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Specific Diagnostics company profile →
Mucosis
HQ: The Netherlands
Website
- Description: Provider of clinical-stage mucosal vaccines delivered needle-free via the nose or mouth, including SynGEM®, an intranasal vaccine candidate to prevent respiratory syncytial virus infection.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Mucosis company profile →
Ondine Biomedical
HQ: Canada
Website
- Description: Provider of non-antibiotic, anti-infective therapies for bacterial, viral, and fungal infections, including Steriwave nasal decolonization that eradicates pathogens in minutes (MRSA, SARS-CoV-2), Photodisinfection using a photosensitive agent and non-thermal laser light to destroy pathogens without resistance, and an Expanded Access Program for investigational medicines prior to regulatory approval.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ondine Biomedical company profile →
Bacterial Barcodes
HQ: United States
Website
- Description: Provider of equipment, reagents, and software for microbial genotyping of bacteria and fungi, packaged as the DiversiLab System, serving the clinical diagnostic market for bacterial identification.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Bacterial Barcodes company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Prosetta Biosciences
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Prosetta Biosciences
2.2 - Growth funds investing in similar companies to Prosetta Biosciences
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Prosetta Biosciences
4.2 - Public trading comparable groups for Prosetta Biosciences
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →